Sonnet Biotherapeutics Holdings, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Sonnet Biotherapeutics Holdings, Inc. files an amended annual report (10-K/A) for the fiscal year ended September 30, 2025, primarily to correct the auditor's report.
Sonnet BioTherapeutics reported a significant increase in net loss for fiscal year 2025, driven by higher R&D and administrative costs, while advancing its oncology pipeline and completing a business combination.
Sonnet BioTherapeutics, a clinical-stage oncology company, reported significant progress in its clinical programs and strategic initiatives for fiscal year 2024, despite facing financial challenges.